Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Return on Equity (2016 - 2025)

Historic Return on Equity for Ligand Pharmaceuticals (LGND) over the last 13 years, with Q3 2025 value amounting to 0.05%.

  • Ligand Pharmaceuticals' Return on Equity changed N/A to 0.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.05%, marking a year-over-year change of. This contributed to the annual value of 0.01% for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Return on Equity is 0.05%.
  • In the past 5 years, Ligand Pharmaceuticals' Return on Equity ranged from a high of 0.05% in Q3 2025 and a low of 0.09% during Q1 2025
  • Over the past 5 years, Ligand Pharmaceuticals' median Return on Equity value was 0.02% (recorded in 2021), while the average stood at 0.02%.
  • Its Return on Equity has fluctuated over the past 5 years, first soared by 1200bps in 2021, then tumbled by -600bps in 2022.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Return on Equity stood at 0.02% in 2021, then tumbled by -69bps to 0.04% in 2022, then skyrocketed by 94bps to 0.0% in 2023, then tumbled by -1429bps to 0.04% in 2024, then skyrocketed by 247bps to 0.05% in 2025.
  • Its last three reported values are 0.05% in Q3 2025, 0.08% for Q2 2025, and 0.09% during Q1 2025.